Last 12 months
Inside the activity.
0 purchase rows · 39 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 2 |
| Dec 2025 | 0 | 6 |
| Jan 2026 | 0 | 1 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 21 |
| Apr 2026 | 0 | 7 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 16, 2018 Filed Feb 20, 2018 21:03 UTC |
Bowden ChristopherChief Medical Officer
|
Exercise / conversionStock option (right to buy) · Derivative | 2,000 | $0.00 Strike: $35.16 | $0.00 |
DisclosureSEC source: 0001209191-18-011244 · doc4.xml · derivative · entry 4 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 Underlying: Common stock · 2,000 shares Expires 2024-05-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · derivative.exercise_date: This option was granted on May 31, 2014. The shares underlying this option vest as to 25% of the underlying shares on May 13, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 16, 2018 Filed Feb 20, 2018 21:03 UTC |
Bowden ChristopherChief Medical Officer
|
SaleCommon stock | 500 | $78.08 | $39,040.00 |
DisclosureSEC source: 0001209191-18-011244 · doc4.xml · nonDerivative · entry 3 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 881 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $78.00 to $78.21. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 16, 2018 Filed Feb 20, 2018 21:03 UTC |
Bowden ChristopherChief Medical Officer
|
SaleCommon stock | 1,500 | $77.51 | $116,265.00 |
DisclosureSEC source: 0001209191-18-011244 · doc4.xml · nonDerivative · entry 2 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,381 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $76.98 to $77.91. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 16, 2018 Filed Feb 20, 2018 21:03 UTC |
Bowden ChristopherChief Medical Officer
|
Exercise / conversionCommon stock | 2,000 | $35.16 | $70,320.00 |
DisclosureSEC source: 0001209191-18-011244 · doc4.xml · nonDerivative · entry 1 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,881 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 16, 2018 Filed Feb 20, 2018 21:02 UTC |
Biller ScottChief Scientific Officer
|
GrantRestricted stock units · Derivative | 8,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-011242 · doc4.xml · derivative · entry 2 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,250 Underlying: Common stock · 8,250 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on February 16, 2018. The shares underlying the restricted stock units will vest in three equal annual installments on February 16, 2019, 2020 and 2021. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F3 · derivative.expiration_date: The restricted stock units were granted on February 16, 2018. The shares underlying the restricted stock units will vest in three equal annual installments on February 16, 2019, 2020 and 2021. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| February 16, 2018 Filed Feb 20, 2018 21:02 UTC |
Biller ScottChief Scientific Officer
|
GrantStock option (right to buy) · Derivative | 33,000 | $0.00 Strike: $77.70 | $0.00 |
DisclosureSEC source: 0001209191-18-011242 · doc4.xml · derivative · entry 1 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,000 Underlying: Common stock · 33,000 shares Expires 2028-02-15 F1 · derivative.exercise_date: This option was granted on February 16, 2018. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2019, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 16, 2018 Filed Feb 20, 2018 21:01 UTC |
Schenkein David PDirector · Chief Executive Officer
|
GrantRestricted stock units · Derivative | 24,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-011239 · doc4.xml · derivative · entry 2 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,375 Underlying: Common stock · 24,375 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on February 16, 2018. The shares underlying the restricted stock units will vest in three equal annual installments on February 16, 2019, 2020 and 2021. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F3 · derivative.expiration_date: The restricted stock units were granted on February 16, 2018. The shares underlying the restricted stock units will vest in three equal annual installments on February 16, 2019, 2020 and 2021. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| February 16, 2018 Filed Feb 20, 2018 21:01 UTC |
Schenkein David PDirector · Chief Executive Officer
|
GrantStock option (right to buy) · Derivative | 97,500 | $0.00 Strike: $77.70 | $0.00 |
DisclosureSEC source: 0001209191-18-011239 · doc4.xml · derivative · entry 1 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,500 Underlying: Common stock · 97,500 shares Expires 2028-02-15 F1 · derivative.exercise_date: This option was granted on February 16, 2018. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2019, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 21:05 UTC |
Biller ScottChief Scientific Officer
|
Exercise / conversionStock options (right to buy) · Derivative | 2,936 | $0.00 Strike: $9.05 | $0.00 |
DisclosureSEC source: 0001209191-18-008108 · doc4.xml · derivative · entry 8 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,154 Underlying: Common stock · 2,936 shares Expires 2023-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F8 · derivative.exercise_date: This option was originally granted on April 30, 2013 for the purchase of 68,181 shares of common stock. The option vests as to 50% of the underlying shares upon the achievement of a performance milestone, and as to the remaining 50% of upon the achievement of a second performance milestone. The Company's board of directors determined that the first performance milestone was achieved on December 3, 2015, resulting in the vesting of this option as to 34,091 shares. On January 26, 2017, the Company's board of directors determined that the second performance milestone was achieved, resulting in the vesting of this option as to the remaining 34,090 shares. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 21:05 UTC |
Biller ScottChief Scientific Officer
|
Exercise / conversionStock options (right to buy) · Derivative | 64 | $0.00 Strike: $0.47 | $0.00 |
DisclosureSEC source: 0001209191-18-008108 · doc4.xml · derivative · entry 7 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,803 Underlying: Common stock · 64 shares Expires 2020-12-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · derivative.exercise_date: This option was granted on December 7, 2010. The shares underlying this option vested as to 25% of the shares upon the achievement of a performance milestone, and as to the remaining 75% in 36 equal monthly installments thereafter. The performance criteria was met on June 23, 2015. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 21:05 UTC |
Biller ScottChief Scientific Officer
|
SaleCommon stock | 400 | $78.03 | $31,212.00 |
DisclosureSEC source: 0001209191-18-008108 · doc4.xml · nonDerivative · entry 6 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,059 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $77.63 to $78.45. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 21:05 UTC |
Biller ScottChief Scientific Officer
|
SaleCommon stock | 701 | $76.76 | $53,808.76 |
DisclosureSEC source: 0001209191-18-008108 · doc4.xml · nonDerivative · entry 5 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,459 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $76.44 to $77.20. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 21:05 UTC |
Biller ScottChief Scientific Officer
|
SaleCommon stock | 1,100 | $75.70 | $83,270.00 |
DisclosureSEC source: 0001209191-18-008108 · doc4.xml · nonDerivative · entry 4 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,160 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $75.31 to $76.26. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 21:05 UTC |
Biller ScottChief Scientific Officer
|
SaleCommon stock | 799 | $74.89 | $59,837.11 |
DisclosureSEC source: 0001209191-18-008108 · doc4.xml · nonDerivative · entry 3 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,260 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $74.16 to $75.06. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 21:05 UTC |
Biller ScottChief Scientific Officer
|
Exercise / conversionCommon stock | 2,936 | $9.05 | $26,570.80 |
DisclosureSEC source: 0001209191-18-008108 · doc4.xml · nonDerivative · entry 2 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,059 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 21:05 UTC |
Biller ScottChief Scientific Officer
|
Exercise / conversionCommon stock | 64 | $0.47 | $29.92 |
DisclosureSEC source: 0001209191-18-008108 · doc4.xml · nonDerivative · entry 1 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,123 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 21:43 UTC |
Bowden ChristopherChief Medical Officer
|
Exercise / conversionStock option (right to buy) · Derivative | 2,000 | $0.00 Strike: $35.16 | $0.00 |
DisclosureSEC source: 0001209191-18-007532 · doc4.xml · derivative · entry 4 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,000 Underlying: Common stock · 2,000 shares Expires 2024-05-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · derivative.exercise_date: This option was granted on May 31, 2014. The shares underlying this option vest as to 25% of the underlying shares on May 13, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 21:43 UTC |
Bowden ChristopherChief Medical Officer
|
SaleCommon stock | 685 | $79.23 | $54,272.55 |
DisclosureSEC source: 0001209191-18-007532 · doc4.xml · nonDerivative · entry 3 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 881 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $79.03 to $79.72. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 21:43 UTC |
Bowden ChristopherChief Medical Officer
|
SaleCommon stock | 1,315 | $78.50 | $103,227.50 |
DisclosureSEC source: 0001209191-18-007532 · doc4.xml · nonDerivative · entry 2 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,566 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $78.01 to $79.00. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 21:43 UTC |
Bowden ChristopherChief Medical Officer
|
Exercise / conversionCommon stock | 2,000 | $35.16 | $70,320.00 |
DisclosureSEC source: 0001209191-18-007532 · doc4.xml · nonDerivative · entry 1 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,881 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 21:40 UTC |
Schenkein David PDirector · Chief Executive Officer
|
Exercise / conversionStock option (right to buy) · Derivative | 13,000 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001209191-18-007529 · doc4.xml · derivative · entry 6 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,567 Underlying: Common stock · 13,000 shares Expires 2019-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · derivative.exercise_date: This option was granted on August 13, 2009. The option vested as to 50% of the underlying shares upon the achievement of a performance milestone, as determined by the issuer's Board of Directors on June 3, 2010, and as to the remaining 50% of the underlying shares in equal monthly installments through June 3, 2013. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 21:40 UTC |
Schenkein David PDirector · Chief Executive Officer
|
SaleCommon stock | 4,460 | $79.23 | $353,365.80 |
DisclosureSEC source: 0001209191-18-007529 · doc4.xml · nonDerivative · entry 3 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $79.03 to $79.72. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 21:40 UTC |
Schenkein David PDirector · Chief Executive Officer
|
SaleCommon stock | 8,540 | $78.50 | $670,390.00 |
DisclosureSEC source: 0001209191-18-007529 · doc4.xml · nonDerivative · entry 2 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,460 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $78.01 to $79.00. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 21:40 UTC |
Schenkein David PDirector · Chief Executive Officer
|
Exercise / conversionCommon stock | 13,000 | $0.30 | $3,932.50 |
DisclosureSEC source: 0001209191-18-007529 · doc4.xml · nonDerivative · entry 1 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| January 26, 2018 Filed Jan 30, 2018 21:26 UTC |
Schenkein David PDirector · Chief Executive Officer
|
Exercise / conversionStock option (right to buy) · Derivative | 23,572 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001209191-18-006004 · doc4.xml · derivative · entry 7 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,567 Underlying: Common stock · 23,572 shares Expires 2019-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F8 · derivative.exercise_date: This option was granted on August 13, 2009. The option vested as to 50% of the underlying shares upon the achievement of a performance milestone, as determined by the issuer's Board of Directors on June 3, 2010, and as to the remaining 50% of the underlying shares in equal monthly installments through June 3, 2013. Read SEC document |
| January 26, 2018 Filed Jan 30, 2018 21:26 UTC |
Schenkein David PDirector · Chief Executive Officer
|
SaleCommon stock | 2,966 | $82.22 | $243,864.52 |
DisclosureSEC source: 0001209191-18-006004 · doc4.xml · nonDerivative · entry 4 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $82.00 to $82.62. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 26, 2018 Filed Jan 30, 2018 21:26 UTC |
Schenkein David PDirector · Chief Executive Officer
|
SaleCommon stock | 11,369 | $81.40 | $925,436.60 |
DisclosureSEC source: 0001209191-18-006004 · doc4.xml · nonDerivative · entry 3 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,966 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $81.00 to $81.95. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 26, 2018 Filed Jan 30, 2018 21:26 UTC |
Schenkein David PDirector · Chief Executive Officer
|
SaleCommon stock | 9,237 | $80.35 | $742,192.95 |
DisclosureSEC source: 0001209191-18-006004 · doc4.xml · nonDerivative · entry 2 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,335 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $80.00 to $80.96. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 26, 2018 Filed Jan 30, 2018 21:26 UTC |
Schenkein David PDirector · Chief Executive Officer
|
Exercise / conversionCommon stock | 23,572 | $0.30 | $7,130.53 |
DisclosureSEC source: 0001209191-18-006004 · doc4.xml · nonDerivative · entry 1 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,572 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| January 24, 2018 Filed Jan 25, 2018 21:03 UTC |
Schenkein David PDirector · Chief Executive Officer
|
Exercise / conversionStock option (right to buy) · Derivative | 13,533 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001209191-18-005357 · doc4.xml · derivative · entry 8 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,159 Underlying: Common stock · 13,533 shares Expires 2019-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F8 · derivative.exercise_date: This option was granted on August 13, 2009. The option vested as to 50% of the underlying shares upon the achievement of a performance milestone, as determined by the issuer's Board of Directors on June 3, 2010, and as to the remaining 50% of the underlying shares in equal monthly installments through June 3, 2013. Read SEC document |
| January 24, 2018 Filed Jan 25, 2018 21:03 UTC |
Schenkein David PDirector · Chief Executive Officer
|
SaleCommon stock | 13,533 | $80.01 | $1,082,775.33 |
DisclosureSEC source: 0001209191-18-005357 · doc4.xml · nonDerivative · entry 4 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $80.00 to $80.07. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 24, 2018 Filed Jan 25, 2018 21:03 UTC |
Schenkein David PDirector · Chief Executive Officer
|
Exercise / conversionCommon stock | 13,533 | $0.30 | $4,093.73 |
DisclosureSEC source: 0001209191-18-005357 · doc4.xml · nonDerivative · entry 3 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,533 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 21:22 UTC |
Schenkein David PDirector · Chief Executive Officer
|
Exercise / conversionStock option (right to buy) · Derivative | 20 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001209191-18-005584 · doc4.xml · derivative · entry 5 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,139 Underlying: Common stock · 20 shares Expires 2019-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · derivative.exercise_date: This option was granted on August 13, 2009. The option vested as to 50% of the underlying shares upon the achievement of a performance milestone, as determined by the issuer's Board of Directors on June 3, 2010, and as to the remaining 50% of the underlying shares in equal monthly installments through June 3, 2013. Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 21:22 UTC |
Schenkein David PDirector · Chief Executive Officer
|
SaleCommon stock | 20 | $80.01 | $1,600.20 |
DisclosureSEC source: 0001209191-18-005584 · doc4.xml · nonDerivative · entry 2 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $80.00 to $80.07. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 21:22 UTC |
Schenkein David PDirector · Chief Executive Officer
|
Exercise / conversionCommon stock | 20 | $0.30 | $6.05 |
DisclosureSEC source: 0001209191-18-005584 · doc4.xml · nonDerivative · entry 1 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| January 23, 2018 Filed Jan 23, 2018 16:35 UTC |
CELGENE CORP /DE/10% owner
Celgene Switzerland LLC10% owner
Celgene Alpine Investment Co., LLC10% owner
Celgene European Investment Co LLC10% owner
|
PurchaseCommon Stock | 851,154 | $67.00 | $57,027,318.00 |
DisclosureSEC source: 0001209191-18-004895 · doc4.xml · nonDerivative · entry 1 CELGENE CORP /DE/ · CIK 0000816284 · 10% owner Celgene Switzerland LLC · CIK 0001661486 · 10% owner Celgene Alpine Investment Co., LLC · CIK 0001581774 · 10% owner Celgene European Investment Co LLC · CIK 0001577650 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,374,599 Read SEC document |
| January 23, 2018 Filed Jan 25, 2018 22:16 UTC Amendment |
Hoerter Steven L.Chief Commercial Officer
|
Exercise / conversionStock option (right to buy) · Derivative | 25,000 | $0.00 Strike: $39.76 | $0.00 |
DisclosureSEC source: 0001209191-18-005432 · doc4a.xml · derivative · entry 1 Hoerter Steven L. · CIK 0001533451 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common stock · 25,000 shares Expires 2016-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · shares: The original Form 4, filed on January 25, 2018, stated that 25,000 derivative securities were acquired as a result of the transaction, when in fact the transaction was a disposition of 25,000 derivative securities. This Form 4 amendment is to solely to correct the nature of the transaction. F3 · derivative.exercise_date: This option was granted on February 16, 2016. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| January 23, 2018 Filed Jan 25, 2018 21:03 UTC |
Hoerter Steven L.Chief Commercial Officer
|
Exercise / conversionStock option (right to buy) · Derivative | 25,000 | $0.00 Strike: $39.76 | $0.00 |
DisclosureSEC source: 0001209191-18-005360 · doc4.xml · derivative · entry 3 Hoerter Steven L. · CIK 0001533451 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common stock · 25,000 shares Expires 2026-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · derivative.exercise_date: This option was granted on February 16, 2016. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| January 23, 2018 Filed Jan 25, 2018 21:03 UTC |
Hoerter Steven L.Chief Commercial Officer
|
SaleCommon stock | 25,000 | $74.83 | $1,870,750.00 |
DisclosureSEC source: 0001209191-18-005360 · doc4.xml · nonDerivative · entry 2 Hoerter Steven L. · CIK 0001533451 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| January 23, 2018 Filed Jan 25, 2018 21:03 UTC |
Hoerter Steven L.Chief Commercial Officer
|
Exercise / conversionCommon stock | 25,000 | $39.76 | $994,000.00 |
DisclosureSEC source: 0001209191-18-005360 · doc4.xml · nonDerivative · entry 1 Hoerter Steven L. · CIK 0001533451 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| January 23, 2018 Filed Jan 25, 2018 21:03 UTC |
Schenkein David PDirector · Chief Executive Officer
|
Exercise / conversionStock option (right to buy) · Derivative | 32,875 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001209191-18-005357 · doc4.xml · derivative · entry 7 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,962 Underlying: Common stock · 32,875 shares Expires 2019-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · derivative.exercise_date: This option was granted on August 13, 2009. The shares underlying this option vest as to 25% of the shares on August 1, 2010, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| January 23, 2018 Filed Jan 25, 2018 21:03 UTC |
Schenkein David PDirector · Chief Executive Officer
|
SaleCommon stock | 32,875 | $80.01 | $2,630,328.75 |
DisclosureSEC source: 0001209191-18-005357 · doc4.xml · nonDerivative · entry 2 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $80.00 to $80.10. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 23, 2018 Filed Jan 25, 2018 21:03 UTC |
Schenkein David PDirector · Chief Executive Officer
|
Exercise / conversionCommon stock | 32,875 | $0.30 | $9,944.69 |
DisclosureSEC source: 0001209191-18-005357 · doc4.xml · nonDerivative · entry 1 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| January 23, 2018 Filed Jan 31, 2018 08:39 UTC Amendment |
CELGENE CORP /DE/10% owner
Celgene Switzerland LLC10% owner
Celgene Alpine Investment Co., LLC10% owner
Celgene European Investment Co LLC10% owner
|
PurchaseCommon Stock | 851,154 | $67.00 | $57,027,318.00 |
DisclosureSEC source: 0001209191-18-006131 · doc4a.xml · nonDerivative · entry 1 CELGENE CORP /DE/ · CIK 0000816284 · 10% owner Celgene Switzerland LLC · CIK 0001661486 · 10% owner Celgene Alpine Investment Co., LLC · CIK 0001581774 · 10% owner Celgene European Investment Co LLC · CIK 0001577650 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,374,599 F1 · date: This Form 4 Amendment is being submitted to correct the date of earliest transaction in box 3 to reflect January 23, 2018. Read SEC document |
| January 16, 2018 Filed Jan 16, 2018 22:16 UTC |
Schenkein David PDirector · Chief Executive Officer
|
Exercise / conversionStock option (right to buy) · Derivative | 53,000 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001209191-18-003637 · doc4.xml · derivative · entry 8 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,692 Underlying: Common stock · 53,000 shares Expires 2019-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F9 · derivative.exercise_date: This option was granted on August 13, 2009. The option vested as to 50% of the underlying shares upon the achievement of a performance milestone, as determined by the issuer's Board of Directors on June 3, 2010, and as to the remaining 50% of the underlying shares in equal monthly installments through June 3, 2013. Read SEC document |
| January 16, 2018 Filed Jan 16, 2018 22:16 UTC |
Schenkein David PDirector · Chief Executive Officer
|
SaleCommon stock | 6,597 | $74.80 | $493,455.60 |
DisclosureSEC source: 0001209191-18-003637 · doc4.xml · nonDerivative · entry 5 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $74.56 to $75.07. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 16, 2018 Filed Jan 16, 2018 22:16 UTC |
Schenkein David PDirector · Chief Executive Officer
|
SaleCommon stock | 10,914 | $74.11 | $808,836.54 |
DisclosureSEC source: 0001209191-18-003637 · doc4.xml · nonDerivative · entry 4 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,597 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $73.56 to $74.55. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 16, 2018 Filed Jan 16, 2018 22:16 UTC |
Schenkein David PDirector · Chief Executive Officer
|
SaleCommon stock | 22,304 | $73.02 | $1,628,638.08 |
DisclosureSEC source: 0001209191-18-003637 · doc4.xml · nonDerivative · entry 3 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,511 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $72.56 to $73.55. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 16, 2018 Filed Jan 16, 2018 22:16 UTC |
Schenkein David PDirector · Chief Executive Officer
|
SaleCommon stock | 13,185 | $71.77 | $946,287.45 |
DisclosureSEC source: 0001209191-18-003637 · doc4.xml · nonDerivative · entry 2 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,815 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $71.50 to $72.42. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 16, 2018 Filed Jan 16, 2018 22:16 UTC |
Schenkein David PDirector · Chief Executive Officer
|
Exercise / conversionCommon stock | 53,000 | $0.30 | $16,032.50 |
DisclosureSEC source: 0001209191-18-003637 · doc4.xml · nonDerivative · entry 1 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.